Symbols / BMY
BMY Chart
About
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 124.29B |
| Enterprise Value | 161.99B | Income | 7.05B | Sales | 48.19B |
| Book/sh | 9.07 | Cash/sh | 5.24 | Dividend Yield | 4.09% |
| Payout | 71.97% | Employees | 32500 | IPO | — |
| P/E | 17.64 | Forward P/E | 9.97 | PEG | — |
| P/S | 2.58 | P/B | 6.73 | P/C | — |
| EV/EBITDA | 8.47 | EV/Sales | 3.36 | Quick Ratio | 1.08 |
| Current Ratio | 1.25 | Debt/Eq | 254.98 | LT Debt/Eq | — |
| EPS (ttm) | 3.46 | EPS next Y | 6.12 | EPS Growth | 13.92% |
| Revenue Growth | 1.30% | Earnings | 2026-04-30 | ROA | 10.29% |
| ROE | 40.44% | ROIC | — | Gross Margin | 72.62% |
| Oper. Margin | 28.16% | Profit Margin | 14.64% | Shs Outstand | 2.04B |
| Shs Float | 2.03B | Short Float | 1.47% | Short Ratio | 2.42 |
| Short Interest | — | 52W High | 63.33 | 52W Low | 42.52 |
| Beta | 0.29 | Avg Volume | 14.41M | Volume | 7.09M |
| Target Price | $61.83 | Recom | Buy | Prev Close | $61.60 |
| Price | $61.03 | Change | -0.93% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$61.83
Mean price target
2. Current target
$61.03
Latest analyst target
3. DCF / Fair value
$98.53
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$61.03
Low
$40.00
High
$75.00
Mean
$61.83
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-25 | init | RBC Capital | — → Sector Perform | $60 |
| 2026-02-23 | main | Piper Sandler | Overweight → Overweight | $75 |
| 2026-02-20 | init | Barclays | — → Overweight | $75 |
| 2026-02-06 | main | Citigroup | Neutral → Neutral | $64 |
| 2026-02-06 | main | Wells Fargo | Equal-Weight → Equal-Weight | $60 |
| 2026-02-06 | main | Guggenheim | Buy → Buy | $72 |
| 2026-01-28 | main | Piper Sandler | Overweight → Overweight | $66 |
| 2026-01-27 | main | Citigroup | Neutral → Neutral | $60 |
| 2026-01-13 | main | Leerink Partners | Outperform → Outperform | $60 |
| 2026-01-09 | main | Scotiabank | Sector Perform → Sector Perform | $60 |
| 2026-01-07 | main | Citigroup | Neutral → Neutral | $53 |
| 2026-01-07 | up | UBS | Neutral → Buy | $65 |
| 2025-12-15 | up | B of A Securities | Neutral → Buy | $61 |
| 2025-12-12 | main | Morgan Stanley | Underweight → Underweight | $37 |
| 2025-12-12 | up | Guggenheim | Neutral → Buy | $62 |
| 2025-12-10 | main | Wells Fargo | Equal-Weight → Equal-Weight | $55 |
| 2025-12-04 | main | Scotiabank | Sector Perform → Sector Perform | $53 |
| 2025-12-02 | main | Goldman Sachs | Neutral → Neutral | $57 |
| 2025-11-17 | main | Citigroup | Neutral → Neutral | $45 |
| 2025-08-01 | main | Citigroup | Neutral → Neutral | $47 |
News
RSS: Latest BMY news- Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock - Yahoo Finance Wed, 25 Feb 2026 14
- A Look At Bristol Myers Squibb (BMY) Valuation After Recent Reblozyl And Iberdomide Milestones - simplywall.st Wed, 25 Feb 2026 16
- BMY: RBC Capital Initiates Coverage with Sector Perform Rating | - GuruFocus Wed, 25 Feb 2026 15
- RBC initiates Bristol-Myers Squibb stock at Sector Perform, $60 target - Investing.com ue, 24 Feb 2026 22
- Dana Investment Advisors Inc. Sells 54,542 Shares of Bristol Myers Squibb Company $BMY - MarketBeat Wed, 25 Feb 2026 09
- CHF 42.54 volume spike: BMY.SW (Bristol-Myers) on SIX 25 Feb 2026, watch support - Meyka Wed, 25 Feb 2026 10
- Pharma Giant Rises In Buy Zone On Better-Than-Feared Guide - Investor's Business Daily hu, 05 Feb 2026 08
- Bristol-Myers: I'm Buying Post Earnings (NYSE:BMY) - Seeking Alpha hu, 19 Feb 2026 21
- How Bristol-Myers Squibb Stock Gained 30% - Trefis Sat, 07 Feb 2026 08
- 3 Stocks to Buy and Hold for 2026 and Beyond - The Motley Fool hu, 19 Feb 2026 17
- Piper Sandler raises Bristol-Myers Squibb stock price target to $75 - Investing.com Mon, 23 Feb 2026 14
- Citigroup Inc. Lowers Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat Sun, 22 Feb 2026 09
- BofA Upgrades Bristol-Myers Squibb (BMY) Stock to Buy from Neutral - Yahoo Finance Sun, 21 Dec 2025 08
- Bristol-Myers Squibb (BMY) Gets Price Target Raise by Piper Sand - GuruFocus Mon, 23 Feb 2026 16
- Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength (NYSE:BMY) - Seeking Alpha hu, 19 Feb 2026 16
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10079 | — | — | HICKEY BENJAMIN J | Officer | — | 2026-01-30 00:00:00 | D | nan |
| 1 | 2543 | — | — | MEYERS GREGORY SCOTT | Chief Technology Officer | — | 2026-01-30 00:00:00 | D | nan |
| 2 | 6281 | — | — | MEYERS GREGORY SCOTT | Chief Technology Officer | — | 2025-10-31 00:00:00 | D | nan |
| 3 | 6281 | — | — | SHANAHAN KARIN | Officer | — | 2025-10-31 00:00:00 | D | nan |
| 4 | 2964 | — | — | BOERNER CHRISTOPHER S | Chief Executive Officer | — | 2025-10-31 00:00:00 | D | nan |
| 5 | 4558 | — | — | GALLMAN CARI | General Counsel | — | 2025-10-02 00:00:00 | D | nan |
| 6 | 56000 | — | Sale at price 47.33 per share. | ELKINS DAVID VINCENT | Chief Financial Officer | — | 2025-09-02 00:00:00 | D | 2650480.0 |
| 7 | 1235 | — | — | SHORT BARTIE WENDY | Officer | — | 2025-08-29 00:00:00 | D | nan |
| 8 | 1061 | — | — | GALLMAN CARI | General Counsel | — | 2025-08-01 00:00:00 | D | nan |
| 9 | 738 | — | — | SHORT BARTIE WENDY | Officer | — | 2025-08-01 00:00:00 | D | nan |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -1.15B | -2.93B | -41.03M | -388.16M |
| TaxRateForCalcs | 0.24 | 0.21 | 0.05 | 0.18 |
| NormalizedEBITDA | 19.95B | 17.10B | 20.24B | 21.41B |
| TotalUnusualItems | -4.71B | -13.93B | -873.00M | -2.19B |
| TotalUnusualItemsExcludingGoodwill | -4.71B | -13.93B | -873.00M | -2.19B |
| NetIncomeFromContinuingOperationNetMinorityInterest | 7.05B | -8.95B | 8.03B | 6.33B |
| ReconciledDepreciation | 4.01B | 9.60B | 9.76B | 10.28B |
| ReconciledCostOfRevenue | 13.24B | 13.24B | 9.98B | 9.46B |
| EBITDA | 15.23B | 3.17B | 19.37B | 19.22B |
| EBIT | 11.22B | -6.43B | 9.61B | 8.95B |
| NetInterestIncome | -1.89B | -1.95B | -1.17B | -1.23B |
| InterestExpense | 1.89B | 1.95B | 1.17B | 1.23B |
| NormalizedIncome | 10.62B | 2.06B | 8.86B | 8.13B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 7.05B | -8.95B | 8.03B | 6.33B |
| TotalExpenses | 34.47B | 42.41B | 36.81B | 37.05B |
| DilutedAverageShares | 2.04B | 2.03B | 2.08B | 2.15B |
| BasicAverageShares | 2.03B | 2.03B | 2.07B | 2.13B |
| DilutedEPS | 3.46 | -4.41 | 3.86 | 2.95 |
| BasicEPS | 3.47 | -4.41 | 3.88 | 2.97 |
| DilutedNIAvailtoComStockholders | 7.05B | -8.95B | 8.03B | 6.33B |
| NetIncomeCommonStockholders | 7.05B | -8.95B | 8.03B | 6.33B |
| NetIncome | 7.05B | -8.95B | 8.03B | 6.33B |
| MinorityInterests | -2.00M | -15.00M | -15.00M | -18.00M |
| NetIncomeIncludingNoncontrollingInterests | 7.05B | -8.93B | 8.04B | 6.34B |
| NetIncomeContinuousOperations | 7.05B | -8.93B | 8.04B | 6.34B |
| TaxProvision | 2.27B | 554.00M | 400.00M | 1.37B |
| PretaxIncome | 9.33B | -8.38B | 8.44B | 7.71B |
| OtherIncomeExpense | -2.50B | -12.32B | 1.41B | -159.00M |
| OtherNonOperatingIncomeExpenses | 2.21B | 1.61B | 2.28B | 2.03B |
| SpecialIncomeCharges | -5.22B | -14.43B | -1.16B | -1.56B |
| GainOnSaleOfBusiness | -15.00M | 0.00 | 211.00M | 9.00M |
| OtherSpecialCharges | 434.00M | 84.00M | -390.00M | 444.00M |
| ImpairmentOfCapitalAssets | 47.00M | 29.00M | 0.00 | 0.00 |
| RestructuringAndMergernAcquisition | 4.79B | 14.34B | 1.55B | 1.33B |
| EarningsFromEquityInterest | -160.00M | -801.00M | 745.00M | |
| GainOnSaleOfSecurity | 510.00M | 494.00M | 289.00M | -630.00M |
| NetNonOperatingInterestIncomeExpense | -1.89B | -1.95B | -1.17B | -1.23B |
| InterestExpenseNonOperating | 1.89B | 1.95B | 1.17B | 1.23B |
| OperatingIncome | 13.72B | 5.89B | 8.20B | 9.10B |
| OperatingExpense | 20.54B | 28.45B | 26.12B | 26.92B |
| OtherTaxes | 0.00 | |||
| DepreciationAmortizationDepletionIncomeStatement | 3.32B | 8.87B | 9.05B | 9.60B |
| DepreciationAndAmortizationInIncomeStatement | 3.32B | 8.87B | 9.05B | 9.60B |
| Amortization | 3.32B | 8.87B | 9.05B | 9.60B |
| AmortizationOfIntangiblesIncomeStatement | 3.32B | 8.87B | 9.05B | 9.60B |
| ResearchAndDevelopment | 9.95B | 11.16B | 9.30B | 9.51B |
| SellingGeneralAndAdministration | 7.27B | 8.41B | 7.77B | 7.81B |
| SellingAndMarketingExpense | 7.81B | 7.69B | ||
| GeneralAndAdministrativeExpense | 7.81B | 7.67B | ||
| OtherGandA | 7.81B | 7.69B | ||
| SalariesAndWages | -15.00M | |||
| GrossProfit | 34.26B | 34.33B | 34.31B | 36.02B |
| CostOfRevenue | 13.94B | 13.97B | 10.69B | 10.14B |
| TotalRevenue | 48.20B | 48.30B | 45.01B | 46.16B |
| OperatingRevenue | 47.20B | 47.26B | 44.39B | 45.41B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 887.00M | 894.00M | 902.00M | 825.00M |
| PreferredSharesNumber | 3.48K | 3.48K | 3.48K | 3.48K |
| OrdinarySharesNumber | 2.04B | 2.03B | 2.02B | 2.08B |
| ShareIssued | 2.92B | 2.92B | 2.92B | 2.90B |
| NetDebt | 34.90B | 39.30B | 28.31B | 30.20B |
| TotalDebt | 47.14B | 51.20B | 41.46B | 40.72B |
| TangibleBookValue | -22.63B | -29.03B | -19.22B | -26.44B |
| InvestedCapital | 63.58B | 65.98B | 69.20B | 70.38B |
| WorkingCapital | 5.97B | 6.01B | 9.51B | 5.38B |
| NetTangibleAssets | -22.63B | -29.03B | -19.22B | -26.44B |
| CapitalLeaseObligations | 2.03B | 1.55B | 1.69B | 1.40B |
| CommonStockEquity | 18.47B | 16.34B | 29.43B | 31.06B |
| TotalCapitalization | 61.32B | 63.94B | 66.08B | 66.12B |
| TotalEquityGrossMinorityInterest | 18.51B | 16.39B | 29.48B | 31.12B |
| MinorityInterest | 33.00M | 53.00M | 55.00M | 57.00M |
| StockholdersEquity | 18.47B | 16.34B | 29.43B | 31.06B |
| GainsLossesNotAffectingRetainedEarnings | -1.52B | -1.24B | -1.55B | -1.28B |
| OtherEquityAdjustments | 40.00M | 378.00M | 4.00M | 232.00M |
| ForeignCurrencyTranslationAdjustments | -997.00M | -968.00M | -812.00M | -890.00M |
| MinimumPensionLiabilities | -566.00M | -648.00M | -738.00M | -623.00M |
| TreasuryStock | 43.58B | 43.66B | 43.77B | 38.62B |
| RetainedEarnings | 16.90B | 14.91B | 28.77B | 25.50B |
| AdditionalPaidInCapital | 46.39B | 46.02B | 45.68B | 45.16B |
| CapitalStock | 292.00M | 292.00M | 292.00M | 292.00M |
| CommonStock | 292.00M | 292.00M | 292.00M | 292.00M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 71.53B | 76.22B | 65.67B | 65.70B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 48.12B | 52.44B | 43.41B | 43.81B |
| OtherNonCurrentLiabilities | 824.00M | 522.00M | 396.00M | 303.00M |
| EmployeeBenefits | 330.00M | 400.00M | 480.00M | 402.00M |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 330.00M | 400.00M | 480.00M | 402.00M |
| TradeandOtherPayablesNonCurrent | 1.41B | 1.49B | 3.29B | 3.99B |
| NonCurrentDeferredLiabilities | 878.00M | 1.05B | 1.06B | 2.80B |
| NonCurrentDeferredRevenue | 169.00M | 230.00M | 300.00M | 283.00M |
| NonCurrentDeferredTaxesLiabilities | 222.00M | 369.00M | 338.00M | 2.17B |
| LongTermDebtAndCapitalLeaseObligation | 44.68B | 48.97B | 38.18B | 36.32B |
| LongTermCapitalLeaseObligation | 1.83B | 1.37B | 1.53B | 1.26B |
| LongTermDebt | 42.85B | 47.60B | 36.65B | 35.06B |
| CurrentLiabilities | 23.42B | 23.77B | 22.26B | 21.89B |
| OtherCurrentLiabilities | 13.07B | 12.91B | 11.50B | 10.57B |
| CurrentDebtAndCapitalLeaseObligation | 2.46B | 2.23B | 3.28B | 4.40B |
| CurrentCapitalLeaseObligation | 202.00M | 181.00M | 162.00M | 136.00M |
| CurrentDebt | 2.26B | 2.05B | 3.12B | 4.26B |
| OtherCurrentBorrowings | 2.26B | 2.05B | 3.12B | 4.26B |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.56B | 1.69B | 1.29B | 1.43B |
| PayablesAndAccruedExpenses | 6.32B | 6.95B | 6.19B | 5.50B |
| CurrentAccruedExpenses | 484.00M | 572.00M | 349.00M | 321.00M |
| InterestPayable | 484.00M | 572.00M | 349.00M | 321.00M |
| Payables | 5.84B | 6.37B | 5.84B | 5.18B |
| DividendsPayable | 1.28B | 1.26B | 1.21B | 1.20B |
| TotalTaxPayable | 979.00M | 1.51B | 1.37B | 942.00M |
| IncomeTaxPayable | 979.00M | 1.51B | 1.37B | 942.00M |
| AccountsPayable | 3.58B | 3.60B | 3.26B | 3.04B |
| TotalAssets | 90.04B | 92.60B | 95.16B | 96.82B |
| TotalNonCurrentAssets | 60.65B | 62.82B | 63.39B | 69.55B |
| OtherNonCurrentAssets | 2.20B | 2.12B | 1.15B | 752.00M |
| DefinedPensionBenefit | 330.00M | 234.00M | 284.00M | 285.00M |
| NonCurrentDeferredAssets | 5.38B | 4.24B | 2.77B | 1.34B |
| NonCurrentDeferredTaxesAssets | 5.38B | 4.24B | 2.77B | 1.34B |
| NonCurrentAccountsReceivable | 436.00M | |||
| InvestmentsAndAdvances | 2.51B | 2.51B | 2.50B | 2.19B |
| InvestmentinFinancialAssets | 411.00M | 772.00M | 800.00M | 0.00 |
| HeldToMaturitySecurities | 15.00M | 452.00M | 436.00M | 0.00 |
| AvailableForSaleSecurities | 396.00M | 320.00M | 364.00M | 2.71B |
| LongTermEquityInvestment | 2.10B | 1.74B | 1.70B | 2.19B |
| GoodwillAndOtherIntangibleAssets | 41.11B | 45.36B | 48.65B | 57.50B |
| OtherIntangibleAssets | 19.35B | 23.64B | 27.48B | 36.35B |
| Goodwill | 21.75B | 21.72B | 21.17B | 21.15B |
| NetPPE | 9.12B | 8.36B | 8.04B | 7.47B |
| AccumulatedDepreciation | -5.29B | -4.95B | -4.80B | -4.16B |
| GrossPPE | 14.42B | 13.31B | 12.84B | 11.64B |
| ConstructionInProgress | 1.62B | 1.52B | 1.07B | 1.05B |
| OtherProperties | 1.58B | 1.22B | 1.39B | 1.22B |
| MachineryFurnitureEquipment | 3.79B | 3.82B | 3.72B | 3.28B |
| BuildingsAndImprovements | 7.27B | 6.58B | 6.50B | 5.92B |
| LandAndImprovements | 157.00M | 161.00M | 162.00M | 162.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 29.39B | 29.78B | 31.77B | 27.27B |
| OtherCurrentAssets | 1.50B | 1.94B | 1.51B | 1.60B |
| RestrictedCash | 0.00 | 55.00M | 148.00M | 140.00M |
| Inventory | 2.69B | 2.56B | 2.66B | 2.34B |
| OtherInventories | -484.00M | -909.00M | ||
| FinishedGoods | 509.00M | 543.00M | ||
| WorkInProcess | 1.85B | 2.11B | ||
| RawMaterials | 464.00M | 350.00M | ||
| Receivables | 14.53B | 14.42B | 15.26B | 13.94B |
| OtherReceivables | 2.01B | 2.12B | 2.46B | 2.24B |
| TaxesReceivable | 2.92B | 3.29B | 3.93B | 3.55B |
| AccountsReceivable | 9.59B | 9.01B | 8.88B | 8.15B |
| AllowanceForDoubtfulAccountsReceivable | -1.78B | -945.00M | -669.00M | -697.00M |
| GrossAccountsReceivable | 11.37B | 9.96B | 9.55B | 8.85B |
| CashCashEquivalentsAndShortTermInvestments | 10.67B | 10.86B | 12.28B | 9.25B |
| OtherShortTermInvestments | 464.00M | 513.00M | 816.00M | 130.00M |
| CashAndCashEquivalents | 10.21B | 10.35B | 11.46B | 9.12B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 12.85B | 13.94B | 12.65B | 11.95B |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -5.16B | -8.00B |
| RepaymentOfDebt | -10.94B | -5.87B | -4.00B | -11.43B |
| IssuanceOfDebt | 5.76B | 15.97B | 4.46B | 6.12B |
| CapitalExpenditure | -1.31B | -1.25B | -1.21B | -1.12B |
| EndCashPosition | 10.22B | 10.35B | 11.52B | 9.32B |
| BeginningCashPosition | 10.35B | 11.52B | 9.32B | 14.32B |
| EffectOfExchangeRateChanges | 195.00M | -137.00M | 45.00M | -33.00M |
| ChangesInCash | -324.00M | -1.03B | 2.15B | -4.96B |
| FinancingCashFlow | -10.35B | 5.13B | -9.42B | -16.96B |
| CashFlowFromContinuingFinancingActivities | -10.35B | 5.13B | -9.42B | -16.96B |
| NetOtherFinancingCharges | 641.00M | |||
| ProceedsFromStockOptionExercised | -128.00M | -106.00M | 27.00M | 984.00M |
| CashDividendsPaid | -5.04B | -4.86B | -4.74B | -4.63B |
| CommonStockDividendPaid | -5.04B | -4.86B | -4.74B | -4.63B |
| NetCommonStockIssuance | 0.00 | 0.00 | -5.16B | -8.00B |
| CommonStockPayments | 0.00 | 0.00 | -5.16B | -8.00B |
| NetIssuancePaymentsOfDebt | -5.17B | 10.10B | 456.00M | -5.31B |
| NetShortTermDebtIssuance | 25.00M | 86.00M | -120.00M | 194.00M |
| ShortTermDebtPayments | 0.00 | -3.00B | -120.00M | 0.00 |
| ShortTermDebtIssuance | 25.00M | 3.09B | 0.00 | 194.00M |
| NetLongTermDebtIssuance | -5.20B | 10.01B | 576.00M | -5.50B |
| LongTermDebtPayments | -10.94B | -2.87B | -3.88B | -11.43B |
| LongTermDebtIssuance | 5.74B | 12.88B | 4.46B | 5.93B |
| InvestingCashFlow | -4.13B | -21.35B | -2.29B | -1.06B |
| CashFlowFromContinuingInvestingActivities | -4.13B | -21.35B | -2.29B | -1.06B |
| NetInvestmentPurchaseAndSale | 52.00M | 618.00M | -826.00M | 3.04B |
| SaleOfInvestment | 2.05B | 1.39B | 948.00M | 6.63B |
| PurchaseOfInvestment | -2.00B | -769.00M | -1.77B | -3.59B |
| NetBusinessPurchaseAndSale | -2.87B | -20.72B | -260.00M | -2.98B |
| SaleOfBusiness | 1.07B | 1.10B | 909.00M | 1.30B |
| PurchaseOfBusiness | -3.94B | -21.82B | -1.17B | -4.29B |
| CapitalExpenditureReported | -1.31B | -1.25B | -1.21B | -1.12B |
| OperatingCashFlow | 14.16B | 15.19B | 13.86B | 13.07B |
| CashFlowFromContinuingOperatingActivities | 14.16B | 15.19B | 13.86B | 13.07B |
| ChangeInWorkingCapital | -455.00M | 810.00M | -1.91B | -2.23B |
| ChangeInOtherWorkingCapital | 30.00M | 2.11B | 237.00M | -183.00M |
| ChangeInPayablesAndAccruedExpense | -6.00M | -1.08B | -405.00M | -1.31B |
| ChangeInPayable | -6.00M | -1.08B | -405.00M | -1.31B |
| ChangeInAccountPayable | -2.00M | 184.00M | 198.00M | 109.00M |
| ChangeInTaxPayable | -4.00M | -1.26B | -603.00M | -1.42B |
| ChangeInIncomeTaxPayable | -4.00M | -1.26B | -603.00M | -1.42B |
| ChangeInInventory | -184.00M | -486.00M | -751.00M | -69.00M |
| ChangeInReceivables | -295.00M | 264.00M | -995.00M | -663.00M |
| OtherNonCashItems | 4.30B | 13.47B | 1.21B | 1.04B |
| StockBasedCompensation | 553.00M | 507.00M | 518.00M | 457.00M |
| AssetImpairmentCharge | 1.10B | 2.96B | 255.00M | 179.00M |
| DeferredTax | -965.00M | -2.09B | -3.29B | -2.74B |
| DeferredIncomeTax | -965.00M | -2.09B | -3.29B | -2.74B |
| DepreciationAmortizationDepletion | 4.01B | 9.60B | 9.76B | 10.28B |
| DepreciationAndAmortization | 4.01B | 9.60B | 9.76B | 10.28B |
| OperatingGainsLosses | -1.45B | -1.14B | -724.00M | -262.00M |
| PensionAndEmployeeBenefitExpense | 35.00M | |||
| EarningsLossesFromEquityInvestments | -280.00M | -16.00M | 160.00M | 801.00M |
| GainLossOnSaleOfBusiness | -1.17B | -1.12B | -884.00M | -1.06B |
| NetIncomeFromContinuingOperations | 7.05B | -8.93B | 8.04B | 6.34B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BMY
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|